C12N 2310/3523
Allyl
C12N2310/3523 (Allyl) appears on 92 US grants and 27 published applications in this corpus.
Search patents in C12N- Granted patents
- 92
- Published applications
- 27
- Assignees
- 16
- Inventors
- 70
- Latest grant
- 6 Oct 2020
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1993 | 1 | 0 |
| 1994 | 1 | 0 |
| 1995 | 2 | 0 |
| 1996 | 8 | 0 |
| 1997 | 18 | 0 |
| 1998 | 13 | 0 |
| 1999 | 8 | 0 |
| 2000 | 9 | 0 |
| 2001 | 4 | 1 |
| 2002 | 13 | 3 |
| 2003 | 3 | 7 |
| 2004 | 2 | 2 |
| 2005 | 3 | 1 |
| 2006 | 4 | 1 |
| 2007 | 1 | 0 |
| 2008 | 0 | 1 |
| 2009 | 0 | 2 |
| 2010 | 0 | 0 |
| 2011 | 0 | 0 |
| 2012 | 0 | 0 |
| 2013 | 0 | 1 |
| 2014 | 0 | 0 |
| 2015 | 0 | 0 |
| 2016 | 1 | 1 |
| 2017 | 0 | 0 |
| 2018 | 0 | 1 |
| 2019 | 0 | 0 |
| 2020 | 1 | 2 |
| 2021 | 0 | 1 |
| 2022 | 0 | 1 |
| 2023 | 0 | 1 |
| 2024 | 0 | 0 |
| 2025 | 0 | 1 |
By publication year. Applications have been published since 2001.
Recent patents
- Method of packing polynucleotides6 Oct 2020US 10,793,889 B2Korea Institute of Science and Technology
- Base modified oligonucleotides16 Aug 2016US 9,416,360 B2Miragen Therapeutics, Inc.
- Derivatized oligonucleotides having improved uptake and other properties26 Jun 2007US 7,235,650 B2Isis Pharmaceuticals, Inc.
- Sugar modified oligonucleotides21 Nov 2006US 7,138,517 B2Isis Pharmaceuticals, Inc.
- Oligonucleotides containing 2′-O-modified purines5 Sep 2006US 7,101,993 B1Isis Pharmaceuticals, Inc.
- Lactate dehydrogenase a (ldha) irna compositions and methods of use thereof16 Jan 2025US 2025/0017953 A1Alnylam Pharmaceuticals, Inc.
- Rnai constructs for inhibiting hsd17b13 expression and methods of use thereof7 Sep 2023US 2023/0279399 A1Amgen Inc.
- Chemically-modified rnai constructs and uses thereof17 Feb 2022US 2022/0049252 A1Amgen Inc.
- Lactate dehydrogenase a (ldha) irna compositions and methods of use thereof29 Jul 2021US 2021/0228614 A1Alnylam Pharmaceuticals, Inc.
- Lactate dehydrogenase a (ldha) irna compositions and methods of use thereof2 Jul 2020US 2020/0206258 A1Alnylam Pharmaceuticals, Inc.
Most cited
By later US patents
- N-2 substituted purines806US 5,459,255 AIsis Pharmaceuticals, Inc. · 1995
- Sugar modified oligonucleotides that detect and modulate gene expression641US 5,670,633 AIsis Pharmaceuticals, Inc. · 1997
- Oligonucleotides having phosphorothioate linkages of high chiral purity626US 5,587,361 AIsis Pharmaceuticals, Inc. · 1996
- Oligonucleotides containing N-2 substituted purines621US 5,587,469 AIsis Pharmaceuticals, Inc. · 1996
- Substituted purines and oligonucleotide cross-linking603US 5,681,941 AIsis Pharmaceuticals, Inc. · 1997